Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122548 | 0.90 | LMNA (0.39) | LMNAFDPSTSHRMMP1MMP2 | |
| SCHEMBL17357044 | 0.74 | HMGCR (0.37) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL17357039 | 0.73 | LMNA (0.35) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL1327181 | 0.73 | LMNA (0.42) | LMNATSHR | |
| SCHEMBL17357046 | 0.72 | GAA (0.40) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL2275330 | 0.69 | LMNA (0.46) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL127431 | 0.69 | MMP1 (0.58) | LMNATSHRMMP1MMP2MMP3 | |
| Phosphoric Acid SCHEMBL31116634 | 0.69 | LMNA (0.47) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL17359390 | 0.69 | TSHR (0.42) | FDPSTSHRMMP1MMP2MMP3 | |
| SCHEMBL6153825 | 0.68 | LMNA (0.45) | LMNATSHRMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296703-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | UNIVERSITY OF UTAH | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | BTK, SYK, LYN | LMNA 4287/4885FDPS 1577/4885TSHR 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.